2005
DOI: 10.1016/j.ab.2005.06.010
|View full text |Cite
|
Sign up to set email alerts
|

Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

8
117
1
12

Year Published

2007
2007
2016
2016

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 139 publications
(138 citation statements)
references
References 34 publications
8
117
1
12
Order By: Relevance
“…3C) thus confirming the increased hepatotoxicity observed in vivo in the PPARβ/δ −/− mouse model (data not shown). To further examine the role of PPARβ/δ activity on conferring resistance to 4-HNE cytotoxicity, immortalized hepatocytes (MuSH WT) were pretreated with either a PPARβ/δ agonist tetradecylthioacetic acid (TTA) or PPAR antagonist GW9662 (at concentrations known to inhibit PPARβ/δ [17]) prior to 4-HNE administration. Pretreating hepatocytes with TTA resulted in a significant protection from 4-HNE-depdendent toxicity (Fig.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…3C) thus confirming the increased hepatotoxicity observed in vivo in the PPARβ/δ −/− mouse model (data not shown). To further examine the role of PPARβ/δ activity on conferring resistance to 4-HNE cytotoxicity, immortalized hepatocytes (MuSH WT) were pretreated with either a PPARβ/δ agonist tetradecylthioacetic acid (TTA) or PPAR antagonist GW9662 (at concentrations known to inhibit PPARβ/δ [17]) prior to 4-HNE administration. Pretreating hepatocytes with TTA resulted in a significant protection from 4-HNE-depdendent toxicity (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…In support, we discovered that oxidized-VLDL and constituents including 13(S)-HODE and 4-HNE are PPARβ/δ agonists. In addition, modulating PPARβ/δ activity, either by activation with synthetic PPARβ/δ-selective agonist tetradecylthioacetic acid (TTA) or inhibition with PPAR pan-antagonist GW9662 [17], affects the sensitivity of hepatocytes to 4-HNE and other toxic agents. This research raises the possibility that PPARβ/δ agonists may be utilized to prevent or treat liver disease associated with the generation of ROIs.…”
Section: Introductionmentioning
confidence: 99%
“…Although useful, selective activation of PPAR isoforms by their synthetic ligands is seriously hampered by their overlapping specificity (34). These ligands have been shown to differentially induce unspecific activation of other PPAR isoforms, or even act PPAR-independent (34). In the present study, by combining PPAR subtype-selective siRNA knockdown with microarray profiling and genome-wide identification of PPREs, we determined isoformselective target gene profiles of PPARs in a cardiomyocyte-like cell type.…”
Section: Discussionmentioning
confidence: 96%
“…Although useful, selective activation of PPAR isoforms by their synthetic ligands is seriously hampered by their overlapping specificity (34). These ligands have been shown to differentially induce unspecific activation of other PPAR isoforms, or even act PPAR-independent (34).…”
Section: Discussionmentioning
confidence: 99%
“…Those tested were carbaprostacyclin (cPGI 2 ), a ligand for both PTGIR and PPARD ( Forman et al 1997); cicaprost, a ligand for PTGIR but not PPARD ( Forman et al 1997); and AFP-07 a high-affinity ligand for PTGIR (Chang et al 1997) but no information available for binding to PPARD. In addition, L165041, a synthetic high-affinity ligand for PPARD without significant binding to PTGIR (Seimandi et al 2005) was used. Since PPARD heterodimerizes with RXRA upon activation, docasahexanoic acid (DHA), a ligand for RXRA (Germain et al 2006) was also included.…”
Section: Introductionmentioning
confidence: 99%